medic
scienc
therebi
place
hand
physician
victori
weapon
ill
death
sinc
antibodi
multipl
form
anim
human
serum
immun
globulin
monoclon
antibodi
develop
primarili
prevent
infecti
diseas
less
commonli
treatment
antibodi
present
tabl
section
review
use
emphasi
valu
treatment
human
infect
summar
tabl
antibodi
work
sever
mechan
neutral
virus
bacteri
toxin
lyse
bacteria
aid
complement
prevent
spread
microb
adjac
cell
along
nerv
root
coat
bacteria
opson
phagocyt
block
microbi
attach
satur
microbi
receptor
facilit
lysi
infect
cell
bind
cytotox
cell
fc
receptor
antibodi
particularli
valuabl
bacteri
diseas
associ
toxin
product
much
tissu
damag
result
action
toxin
neutral
rapidli
antibodi
antibiot
kill
bacterium
anthrax
bacillu
anthraci
anthrax
rare
seriou
infect
predominantli
rumin
anim
caus
aerob
gramposit
rod
human
infect
skin
cutan
anthrax
ingest
gastrointestin
anthrax
inhal
anthrax
spore
inhal
anthrax
last
often
result
prolong
exposur
anim
hide
carcass
infect
soil
rare
deliber
spore
exposur
bioterror
set
inhal
spore
ingest
alveolar
macrophag
transport
region
node
spore
germin
releas
potent
exotoxin
toxin
damag
cell
membran
increas
capillari
permeabl
caus
pulmonari
damag
lead
shock
cardiovascular
collaps
vaccin
avail
individu
high
risk
exposur
militari
antibiot
era
earli
anthrax
antitoxin
usual
equin
use
therapi
antitoxin
valu
bioterror
attack
exposur
us
govern
collect
plasma
immun
donor
develop
human
hightit
igiv
human
monoclon
antibodi
test
anim
human
diphtheria
corynebacterium
diphtheria
mani
advers
effect
diphtheria
result
action
potent
toxin
heart
central
nervou
system
organ
thu
prompt
use
antitoxin
indic
addit
antibiot
dose
use
depend
local
sever
infect
rang
unit
mild
infect
short
durat
unit
sever
ill
neck
edema
equin
antitoxin
given
intraven
must
preced
skin
test
hypersensit
possibl
desensit
antitoxin
avail
us
center
diseas
control
cdc
smaller
dose
antitoxin
use
asymptomat
expos
suscept
individu
avail
diphtheria
vaccin
antitoxin
given
health
care
worker
care
patient
diphtheria
tetanu
clostridium
tetani
equin
antitoxin
treatment
tetanu
initi
von
behr
toxin
neutral
extens
studi
carri
determin
optim
dose
antitoxin
possibl
benefit
intrathec
antitoxin
particularli
tetanu
neonatorum
common
problem
develop
countri
sinc
human
tetanu
immun
globulin
tig
avail
area
world
equin
antitoxin
still
use
tig
given
unimmun
incomplet
immun
patient
sustain
contamin
deep
punctur
wound
recommend
dose
tig
iu
along
initi
activ
immun
tig
unavail
human
ivig
also
use
contain
variabl
titer
tetanu
antitoxin
minim
dose
mgkg
suggest
tetanu
prophylaxi
clostridium
difficil
gastroenter
clostridium
difficil
infect
gastrointestin
tract
usual
associ
antibioticassoci
diarrhea
often
pseudomembran
coliti
sometim
toxic
megacolon
toxic
strain
clostridium
difficil
releas
distinct
toxin
potent
cytotox
inflammatori
properti
infect
gener
lead
antibodi
respons
toxin
individu
older
year
antibodi
high
level
antibodi
acquir
colon
may
result
asymptomat
carrier
state
patient
symptomat
infect
mani
immunodefici
immunosuppress
develop
antibioticresist
diarrhea
mani
low
absent
igg
antibodi
toxin
patient
may
respond
ivig
given
mgkg
everi
week
therapi
increas
antitoxin
level
control
diarrhea
prevent
relaps
control
trial
perform
botul
clostridium
botulinum
botul
sever
paralyt
poison
result
ingest
absorpt
neurotoxin
spore
clostridium
botulinum
sever
variant
recogn
food
poison
ingest
contamin
can
food
wound
botul
contamin
softtissu
infect
inhal
botul
among
individu
work
toxin
bioterrorist
event
infantil
botul
see
next
section
adulttyp
infant
botul
adult
preexist
gastrointestin
diseas
last
type
ingest
spore
multipli
gastrointestin
tract
elabor
toxin
absorb
toxin
result
paralyt
disord
case
botul
associ
use
botul
toxin
cosmet
use
heptaval
fab
fragment
equin
antitoxin
hbat
type
b
c
e
f
g
avail
unit
state
cdc
sensit
test
must
conduct
use
antitoxin
type
given
unless
toxin
type
known
addit
dose
may
need
sever
wound
botul
antitoxin
also
use
prophylact
individu
known
ingest
contamin
food
use
infantil
botul
infantil
botul
clostridium
botulinum
sever
paralyt
disord
infant
result
ingest
clostridium
botulinum
spore
babi
formula
food
result
slow
onset
constip
abdomin
bloat
poor
feed
respiratori
paralysi
infant
must
hospit
prolong
period
tube
feed
respiratori
support
often
long
month
human
iv
botul
immun
globulin
avail
treatment
infantil
botul
despit
high
cost
per
vial
costeffect
shorten
hospit
stay
need
ga
gangren
clostridium
perfringen
antitoxin
ga
gangren
respiratori
infect
streptoccocci
streptococcu
pneumonia
haemophilu
influenza
neisseria
meningitid
reduc
immunodefici
patient
receiv
immunoglobulin
therapi
patient
includ
young
infant
poor
antibodi
respons
polysaccharid
antigen
patient
infect
human
immunodefici
viru
hiv
patient
primari
antibodi
immunodefici
antibiot
immun
serum
anim
serum
use
therapi
sever
bacteri
infect
studi
suggest
larg
dose
ivig
decreas
frequenc
otiti
patient
recurr
otiti
normal
immun
thu
regular
use
ivig
antibodydefici
patient
dose
mgkg
everi
week
equival
amount
given
subcutan
decreas
frequenc
sever
otiti
respiratori
tract
infect
circul
antibodi
may
play
role
prevent
treatment
invas
group
streptococc
infect
newborn
transplacent
antibodi
patient
ivig
rare
develop
streptococc
ill
equin
antitoxin
use
success
treatment
erysipela
scarlet
fever
prevent
vaccin
streptococc
protein
contempl
yet
unavail
treatment
ivig
addit
antibiot
probabl
benefici
streptococc
pyrogen
exotoxin
type
b
c
mitogen
factor
elabor
certain
strain
streptococci
may
respons
complic
exotoxin
potent
superantigen
activ
certain
lymphocyt
directli
lead
synthesi
andor
releas
multipl
cytokin
result
shock
fever
organ
failur
ivig
contain
neutral
antibodi
antigen
vari
titer
batch
batch
despit
variabl
ivig
recommend
addit
antibiot
manag
infect
neutral
pyrogen
toxin
dampen
cytokin
storm
releas
control
trial
unavail
case
report
larg
seri
compar
histor
control
encourag
larg
dose
ivig
recommend
eg
gkg
sever
day
staphylococc
infect
ubiquit
vari
sever
rang
superfici
skin
infect
deepseat
cellul
osteomyel
overwhelm
shock
sever
infect
occur
organ
resist
antibiot
strain
associ
toxin
product
one
wellrecogn
syndrom
toxic
shock
associ
tampon
use
menstruat
women
syndrom
result
releas
toxic
shock
syndrom
potent
superantigen
initi
releas
multipl
cytokin
clinic
pictur
rapidli
progress
fever
shock
organ
failur
author
recommend
high
dose
ivig
neutral
toxin
dampen
cytokin
storm
second
situat
ivig
may
valu
neonat
staphylococc
infect
usual
coagulaseneg
staphylococcu
epidermidi
common
caus
sepsi
prematur
infant
aggrav
part
use
cathet
central
line
one
control
studi
indic
ivig
valu
decreas
incid
infect
studi
confirmatori
possibl
differ
titer
protect
antibodi
immunoglobulin
also
use
treatment
antibioticresist
staphylococc
infect
older
studi
waisbren
current
studi
russia
suggest
clinic
benefit
anim
studi
support
combin
approach
newborn
particularli
prematur
newborn
birth
weight
less
g
potenti
candid
immunoglobulin
therapi
view
frequenc
sever
infect
newborn
low
level
igm
iga
prematur
defici
transplacent
matern
igg
defici
proport
degre
immatur
prematur
infant
also
defect
antibodi
synthesi
complement
level
opson
activ
neutrophil
mobil
kill
cellular
immun
respons
accordingli
sever
studi
sought
determin
valu
igiv
prevent
earli
treatment
infect
prematur
infant
studi
differ
term
entri
criteria
immunoglobulin
dose
durat
end
point
eg
type
sever
infect
surviv
metaanalys
prospect
random
placebocontrol
prevent
studi
suggest
slight
reduct
frequenc
sepsi
differ
mortal
length
nurseri
stay
complic
prematur
contrast
metaanalysi
control
studi
treatment
proven
sepsi
involv
prematur
infant
show
igiv
therapi
reduc
mortal
signific
differ
suggest
benefit
infant
suspect
sepsi
also
infant
neutropenia
may
particularli
benefit
common
caus
neonat
sepsi
staphylococcu
epidermidi
hyperimmun
staphylococc
ivig
may
particular
benefit
prevent
neonat
sepsi
two
recent
studi
igiv
either
immun
donor
altastaph
select
donor
high
titer
fibrinogenbind
protein
veron
show
significantli
decreas
incid
infect
studi
monoclon
antibodi
staphylococc
antigen
progress
thu
nation
institut
health
consensu
statement
igiv
given
routin
infant
low
birth
weight
may
valu
select
prematur
newborn
proven
suspect
infect
remain
valid
patient
undergo
sever
stress
associ
trauma
extens
surgeri
intens
care
profound
exposur
suscept
infect
usual
result
enter
gramneg
infect
monoclon
antibodi
igmenrich
igiv
regular
igiv
studi
situat
inconclus
result
laupland
colleagu
review
random
trial
igiv
found
suggest
benefit
term
length
stay
intens
care
unit
icu
mortal
similar
studi
pediatr
patient
icu
perform
despit
lack
control
trial
igiv
often
use
critic
ill
patient
particularli
neutropen
patient
possibl
benefit
rare
side
effect
although
mani
viral
diseas
prevent
immunoglobulin
amen
antibodi
therapi
present
tabl
section
focus
viral
diseas
antibodi
use
therapi
although
smallpox
variola
erad
world
sinc
immun
live
vaccinia
viru
cowpox
viru
still
use
militari
certain
laboratori
personnel
work
vaccinia
smallpox
potenti
bioterror
weapon
suppli
vaccinia
immun
globulin
vig
stockpil
us
govern
complic
smallpox
vaccin
respons
biolog
warfar
kemp
use
immun
globulin
vaccin
individu
vig
prevent
spread
outbreak
smallpox
madra
india
also
show
vig
could
use
treat
infrequ
complic
smallpox
vaccin
includ
vaccinia
eczematum
gener
vaccinia
autoinocul
prevent
spread
highrisk
individu
expos
recent
vaccin
individu
vig
iv
intramuscular
im
use
prepar
vaccin
donor
commerci
avail
usual
dose
mgkg
parvoviru
dna
viru
caus
fifth
diseas
slap
cheek
syndrom
common
exanthem
childhood
usual
provid
lifelong
immun
subsequ
exposur
parvoviru
infect
erythroid
progenitor
receptor
common
red
cell
p
antigen
caus
red
cell
aplasia
patient
congenit
acquir
immunodefici
includ
hiv
immunosuppress
organ
transplant
recipi
patient
sickl
cell
diseas
igiv
contain
neutral
antibodi
parvoviru
prolong
highdos
therapi
erad
infect
parvoviru
infect
pregnanc
also
caus
fetal
hydrop
arthriti
chronic
fatigu
syndrom
uncommon
manifest
chronic
parvoviru
infect
ivig
dose
need
erad
parvoviru
establish
larg
gkg
repeat
viru
erad
indic
serum
polymeras
chain
reaction
analysi
antibodi
cytomegaloviru
cmv
either
form
hyperimmun
iv
cmv
immun
globulin
cmvigcytogam
regular
igiv
use
decad
prevent
cmv
infect
recipi
bone
marrow
solid
organ
transplant
cmvig
prepar
donor
high
anticmv
titer
regular
igiv
also
contain
cmv
antibodi
lower
titer
test
donor
recipi
cmv
infect
use
cmv
antibodyneg
blood
donor
use
antivir
drug
greatli
reduc
indic
cmv
antibodi
cmvig
still
use
heart
heartlung
transplant
along
antivir
either
donor
recipi
cmvseroposit
cmvig
also
suggest
benefit
sever
cmv
pneumon
along
antivir
treatment
cmvig
may
also
valu
utero
cmv
infect
infus
cmvig
given
intraperiton
week
cmvinfect
fetu
possibl
benefit
nigro
colleagu
gave
pregnant
women
primari
cmv
infect
cmvig
pregnanc
women
receiv
addit
cmvig
amniot
sac
umbil
cord
one
woman
gave
birth
infant
cmv
infect
compar
cmv
infect
infant
control
women
receiv
antibodi
therapi
data
encourag
wellcontrol
studi
thu
use
cmvig
recipi
organ
transplant
sever
cmv
infect
utero
cmv
infect
unprov
suggest
therapeut
benefit
transplacent
matern
antibodi
proven
prevent
effect
herp
simplex
viru
hsv
infect
newborn
period
mother
reactiv
herpex
infect
ie
preexist
infect
deliveri
less
like
transmit
hsv
newborn
infant
vagin
deliveri
mother
primari
hsv
infect
acquir
late
pregnanc
masci
colleagu
use
ivig
prevent
recurr
genit
hsv
infect
suggest
benefit
valu
hsv
monoclon
antibodi
ivig
evalu
treatment
dissemin
neonat
diseas
epsteinbarr
viru
ebv
antibodi
present
variabl
titer
ivig
particularli
cmvig
donor
high
titer
cmv
often
high
titer
ebv
patient
posttranspl
ebvinduc
lymphoprolif
syndrom
hepat
treat
success
combin
igiv
cmvig
antivir
therapi
interferona
similar
result
achiev
ebv
infect
xlink
lymphoprolif
syndrom
patient
hereditari
predisposit
overwhelm
ebv
infect
varicellazost
immun
globulin
vzig
avail
sinc
prepar
plasma
high
titer
vz
viru
commerci
product
varizig
use
prevent
modif
suscept
highrisk
immunodefici
immunosuppress
children
expos
chickenpox
shingl
also
use
suscept
women
late
pregnanc
newborn
infant
whose
mother
develop
chickenpox
perinat
expos
prematur
infant
less
week
gestat
benefit
establish
chickenpox
zoster
infect
encephalomyel
polioviru
vaccin
introduc
immunoglobulin
use
prevent
poliomyel
immunodefici
individu
suscept
chronic
enterovir
enceph
usual
echoviru
coxsackieviru
less
commonli
attenu
polioviru
vaccin
strain
regular
dose
igiv
given
antibodydefici
patient
markedli
reduc
frequenc
enteroviru
enceph
patient
attenu
polioviru
replac
mani
countri
inactiv
salk
vaccin
highdos
ivig
suffici
increas
serum
igg
level
mgml
use
success
immunodefici
patient
enterovir
encephalomyel
patient
given
intrathec
infus
ivigtr
patient
cure
may
viral
strain
ivig
neutral
antibodi
instanc
type
cerebrospin
fluid
treatment
select
ivig
unit
antibodi
infect
serotyp
may
necessari
antivir
therapi
pleconoril
also
use
neonat
enterovir
infect
sever
sometim
fatal
dissemin
enteroviru
infect
develop
neonat
highdos
ivig
use
infant
suggest
benefit
decreas
sever
ill
matern
plasma
may
also
use
likelihood
mother
antibodi
organ
involv
ivig
also
use
prevent
spread
unaffect
infant
nurseri
unless
titer
ivig
known
larg
dose
recommend
increasingli
import
use
hyperimmun
hepat
b
immun
globulin
hbig
prevent
hepat
b
recurr
hepat
bseroposit
recipi
liver
transplant
mani
transplant
complic
hepat
b
hepat
b
reoccur
half
patient
year
recurr
reduc
significantli
give
larg
dose
hbig
prolong
period
begin
time
transplant
continu
indefinit
transplant
antivir
agent
lamivudin
also
given
simultan
dose
hbig
transplant
vari
maintain
continu
serum
antihb
titer
hepat
b
vaccin
also
given
induc
activ
immun
type
hbig
avail
includ
igim
use
prophylaxi
newborn
hepat
bposit
mother
unimmun
expos
suscept
hbig
iv
use
liver
transplant
use
latter
add
consider
cost
liver
transplant
univers
california
lo
angel
medic
center
spend
per
year
hbig
nearli
liver
transplant
program
hyperimmun
hepat
c
immun
globulin
hepat
c
liver
transplant
also
studi
monoclon
antibodi
hepat
b
c
develop
west
nile
fever
west
nile
fever
caus
west
nile
viru
common
mani
tropic
region
culex
mosquito
endem
spread
europ
unit
state
also
transmit
infect
blood
organ
transplant
sever
case
report
anim
studi
suggest
ivig
prepar
seroposit
donor
modifi
sever
mortal
ebola
ebola
viru
filiviru
caus
sever
often
fatal
hemorrhag
fever
tropic
africa
effect
antivir
agent
goat
hyperimmun
serum
protect
guinea
pig
experiment
infect
given
within
hour
exposur
product
use
emerg
prophylaxi
patient
expos
laboratori
accid
one
develop
mild
infect
equin
serum
protect
monkey
lowdos
viru
challeng
highdos
viru
challeng
blood
convalesc
patient
also
use
promis
result
anim
antisera
develop
monoclon
antibodi
tickborn
enceph
tickborn
enceph
caus
flaviviru
endem
central
europ
vaccin
avail
hyperimmun
immun
globulin
combin
also
use
argentin
hemorrhag
fever
argentin
hemorrhag
fever
caus
junin
viru
high
mortal
vascular
neurolog
complic
maiztegui
colleagu
found
immun
plasma
given
ninth
day
ill
reduc
mortal
among
patient
given
immun
plasma
compar
mortal
among
patient
given
normal
plasma
sever
acut
respiratori
distress
syndrom
convalesc
plasma
ivig
use
treatment
sever
acut
respiratori
distress
syndrom
caus
corona
viru
studi
inconclus
antibodi
timehonor
way
prevent
viral
infect
exposur
crucial
role
treatment
bacteri
diseas
associ
toxin
product
also
valu
prevent
certain
viral
infect
well
treatment
parvoviu
enteroviru
infect
certain
region
viral
infect
polyclon
immunoglobulin
use
score
divers
disord
first
use
prevent
infecti
diseas
ogden
bruton
report
child
agammaglobulinemia
initi
first
use
repeat
inject
immunoglobulin
replac
therapi
report
cglobulin
fraction
human
plasma
administ
subcutan
boy
known
cglobulin
serum
protein
electorophoresi
child
multipl
infect
includ
episod
septicemia
amelior
chronic
treatment
immunoglobulin
experi
repres
dawn
immunoglobulin
therapi
primari
immunodefici
defin
use
diseas
therapeut
alter
avail
sinc
studi
primari
immunodefici
expand
markedli
distinct
diagnos
defect
humor
immun
approxim
peopl
live
primari
immunodefici
unit
state
greater
antibodi
defici
potenti
requir
immunoglobulin
replac
therapi
primari
immunodefici
registri
confirm
greater
antibodi
defici
treatment
immunoglobulin
remain
best
therapeut
option
patient
characterist
antibodi
immunodefici
appropri
replac
therapi
present
tabl
clearest
indic
immunoglobulin
therapi
associ
absenc
b
cell
categori
patient
unabl
make
antibodi
immunoglobulin
exampl
includ
agammaglobulinemia
certain
type
sever
combin
immunodefici
sever
gene
defect
may
respons
ill
need
immunoglobulin
replac
therapi
next
categori
ii
patient
need
immunoglobulin
b
cell
make
igg
gener
specif
igg
antibodi
igg
repres
major
defens
humor
immun
infect
patient
also
requir
immunoglobulin
replac
therapi
diagnost
categori
includ
hyper
igm
syndrom
higm
common
variabl
immunodefici
cvid
higm
caus
sever
specif
gene
mutat
cvid
case
identifi
genet
lesion
diagnosi
made
either
identifi
specif
gene
mutat
defin
quantit
qualit
deficit
igg
patient
categori
continu
uninterrupt
replac
therapi
immunoglobulin
warrant
diagnosi
confirm
molecularli
immunoglobulin
therapi
must
continu
case
may
clinic
appropri
stop
immunoglobulin
therapi
lifetim
determin
defect
fix
strategi
repeat
singl
trial
indic
persist
deficit
trial
immunoglobulin
therapi
consid
perform
late
spring
summer
respiratori
infect
less
preval
third
diagnost
categori
iii
antibodi
defici
associ
qualit
defect
humor
immun
patient
b
cell
produc
normal
quantiti
igg
qualiti
igg
diminish
individu
unabl
respond
appropri
specif
antigen
challeng
vaccin
infect
categori
includ
specif
antibodi
defici
normal
immunoglobulin
certain
patient
nemo
nfkappa
b
essenti
modul
defici
diagnosi
made
document
ineffect
vaccin
respons
fail
humor
respons
infect
specif
molecular
genet
diagnosi
link
categori
fourth
categori
iv
includ
patient
lower
expect
level
igg
abl
mount
effect
antibodi
respons
categori
form
subset
individu
refer
isol
hypogammaglobulinemia
igg
level
low
although
hypogammaglobulinemia
compon
mani
immunolog
defect
isol
hypogammaglobulinemia
antibodi
qualiti
adequ
normal
respons
vaccin
infect
normal
agespecif
rang
igg
defin
lower
limit
percentil
one
individu
low
level
igg
question
becom
deficit
antibodi
qualiti
isol
hypogammaglobulinemia
clinic
problem
also
import
discern
hypogammaglobulinemia
repres
primari
versu
secondari
problem
increas
loss
igg
exampl
latter
includ
drain
chylothorax
intestin
lymphangiectasia
individu
hypogammaglobulinemia
less
like
caus
problem
antibodi
synthesi
intact
often
acceler
patient
primari
hypogammaglobulinemia
level
igg
associ
definit
risk
infect
defin
especi
antibodi
qualiti
intact
insur
compani
recommend
replac
therapi
patient
igg
level
less
mgdl
histori
recurr
infect
although
situat
may
reason
question
still
exist
manag
patient
recogn
primari
hypogammaglobulinemia
low
igg
level
ie
histori
infect
diagnost
exampl
includ
transient
hypogammaglobulinemia
infanc
thi
otherwis
unexplain
primari
hypogammaglobulinemia
former
diagnosi
establish
retrospect
igg
level
normal
age
thu
select
case
thi
immunoglobulin
replac
may
consid
tempor
measur
howev
primari
hypogammaglobulinemia
remain
difficult
diagnost
therapeut
dilemma
patient
fifth
diagnost
categori
v
defici
one
major
igg
subclass
defici
common
consid
abnorm
although
defici
one
major
igg
subclass
indic
immunolog
deviat
patient
normal
total
igg
level
intact
respons
specif
antigen
candid
immunoglobulin
replac
therapi
impair
antibodi
specif
fall
categori
third
categori
howev
even
without
impair
antibodi
qualiti
immunoglobulin
replac
patient
defici
subclass
reduc
incid
infect
nevertheless
insur
unit
state
addit
criteria
justifi
therapi
patient
igg
defici
subclass
final
diagnost
categori
patient
recurr
infect
hypogammaglobulinemia
subclass
defici
deficit
antibodi
qualiti
thu
infecti
suscept
without
evid
identifi
immun
abnorm
infecti
burden
individu
high
certainli
explan
nonhumor
diagnos
aggress
sought
also
patient
explan
whose
infecti
suscept
present
evad
clinic
scienc
immunoglobulin
replac
therapi
consid
individu
certain
circumst
immunoglobulin
prepar
antibodi
immunodefici
although
bruton
gave
immunoglobulin
patient
subcutan
sc
rout
subsequ
patient
receiv
immunoglobulin
weekli
im
inject
strategi
necessari
immunoglobulin
prepar
purifi
degre
requir
iv
administr
earli
immunoglobulin
prepar
low
quantiti
immunoglobulin
aggreg
develop
iv
administr
ivig
igiv
numer
advantag
includ
achiev
high
peak
trough
igg
level
conveni
monthli
dose
regimen
although
limit
studi
compar
ivig
imig
iv
rout
becom
prefer
rout
immunoglobulin
administr
worldwid
seven
ivig
prepar
current
approv
us
food
drug
administr
fda
replac
therapi
primari
immunodefici
tabl
studi
licens
trial
patient
primari
immunodefici
found
safe
effect
primari
end
point
clinic
trial
prevent
seriou
bacteri
infect
compar
expect
frequenc
infect
diagnosi
rate
infect
surprisingli
high
shown
bruton
first
patient
mention
earlier
earli
diagnosi
treatment
primari
immunodefici
immunoglobulin
product
reduc
morbid
mortal
consider
save
health
care
expenditur
ivig
product
purifi
human
plasma
pool
strict
manufactur
guidelin
although
manufactur
process
similar
differ
variou
method
process
remov
nonigg
impur
igg
aggreg
add
stabil
prevent
vitro
aggreg
format
despit
effort
advers
reaction
ivig
administr
uncommon
immunoglobulin
manufactur
robust
measur
screen
donor
inactiv
bloodborn
pathogen
safeti
immunoglobulin
prepar
last
decad
superb
subtl
differ
among
differ
ivig
product
differ
compani
sever
compani
one
product
market
situat
lead
confus
ivig
administ
patient
gener
ivig
product
toler
patient
characterist
individu
ivig
prepar
outlin
tabl
may
help
select
best
product
patient
differ
concentr
stabil
sugar
content
iga
content
sodium
content
osmal
volum
individu
vial
storag
requir
need
reconstitut
lyophil
product
use
local
avail
price
also
variabl
mani
patient
may
toler
one
product
effect
anoth
thu
patient
toler
particular
immunoglobulin
product
advis
continu
product
whenev
possibl
three
prepar
immunoglobulin
approv
us
fda
tabl
one
approv
im
administr
two
sc
administr
patient
receiv
immunoglobulin
im
rout
sc
administr
immunoglobulin
resurfac
unit
state
subcutan
immunoglobulin
scig
usual
given
abdomin
wall
thigh
thin
bore
needl
infus
pump
deliv
sever
hour
although
initi
use
unit
state
limit
sc
rout
gain
popular
europ
extens
clinic
experi
indic
equival
ivig
therapi
crossov
trial
ivig
us
fda
licens
trial
show
scig
equival
ivig
prevent
infect
primari
immunodefici
scig
advantag
disadvantag
compar
ivig
therapi
mani
relat
patient
prefer
review
extens
one
advantag
scig
ivig
markedli
decreas
incid
system
reaction
anoth
elimin
need
iv
access
indwel
iv
access
devic
seriou
disadvantag
need
frequent
administr
least
weekli
administ
suffici
immunoglobulin
anoth
disadvantag
less
frequent
physician
encount
scig
infus
given
home
caretak
home
infus
compani
dose
frequenc
immunoglobulin
therapi
complex
topic
draw
evidenceand
experiencebas
sourc
recommend
present
sever
review
consensu
statement
recommend
includ
start
dose
mgkgmo
sever
month
dose
alter
depend
trough
level
clinic
respons
patient
vari
requir
maintain
reason
resist
infect
scig
typic
use
patient
ivig
sever
month
weekli
scig
dose
usual
onefourth
previou
monthli
ivig
dose
immunoglobulinna
patient
start
immunoglobulin
therapi
scig
number
initi
dose
may
need
increas
amount
scig
given
singl
site
adult
usual
ml
solut
ie
g
one
site
use
simultan
deliv
target
dose
procedur
facilit
avail
special
tube
needl
set
cathet
pump
infus
site
reaction
uncommon
rare
sever
ivig
usual
administ
monthli
scig
usual
administ
weekli
schedul
often
use
schedul
includ
shorter
longer
interv
infus
ivig
achiev
satisfactori
clinic
respons
scig
given
biweekli
divid
frequent
inject
even
small
daili
dose
latter
gener
selfadminist
home
well
toler
prefer
patient
small
daili
dose
need
trough
level
immunoglobulin
achiev
must
consid
sever
studi
correl
resist
infect
specif
igg
trough
level
target
specif
trough
level
may
feasibl
patient
agammaglobulinemia
profound
defici
igg
difficult
antibodi
defici
agammaglobulinemia
trough
level
mgdl
minim
accept
level
mgdl
desir
trough
level
recommend
may
appropri
disord
baselin
igg
level
antibodi
titer
variabl
case
clinic
respons
must
consid
polyclon
immunoglobulin
essenti
therapi
primari
antibodi
immunodefici
diseas
differ
disord
immunoglobulin
therapi
use
review
sever
immunoglobulin
product
avail
treatment
similar
therapeut
properti
individu
differ
among
avail
product
immunoglobulin
given
either
intraven
ivig
subcutan
scig
dosag
frequenc
infus
achiev
trough
level
advantag
disadvantag
ivig
scig
discuss
earli
wit
increas
use
ivig
immunomodul
inflammatori
autoimmun
disord
ivig
prescrib
patient
autoimmun
inflammatori
diseas
despit
fact
ivig
approv
hand
indic
box
late
situat
led
ivig
shortag
compromis
patient
depend
igg
replac
therapi
correct
underli
antibodi
defici
american
academi
allergi
asthma
immunolog
committe
primari
immunodefici
evalu
use
ivig
multipl
disord
strength
evid
benefici
effect
basi
recommend
classifi
box
section
review
use
ivig
autoimmun
inflammatori
condit
report
box
context
review
mechan
action
ivig
condit
multipl
effect
ivig
innat
adapt
immun
system
illustr
fig
histor
note
ivig
immun
thrombocytopen
purpura
first
use
ivig
autoimmun
process
children
immun
thrombocytopen
purpura
itp
imbach
colleagu
observ
antibodydefici
patient
receiv
ivig
also
itp
mark
increas
platelet
count
ivig
infus
subsequ
investig
examin
therapeut
effect
ivig
children
primari
diagnosi
itp
use
highdos
ivig
mgkg
consecut
day
investig
report
dramat
increas
platelet
count
within
hour
administr
ivig
patient
increas
platelet
count
sustain
other
repeat
ivig
treatment
necessari
box
present
indic
ivig
autoimmun
cytopenia
well
like
benefit
sever
hypothes
propos
explain
rapid
increas
platelet
count
antibodyco
cell
ivig
administr
accept
hypothesi
highdos
ivig
induc
fc
receptor
blockad
reticuloendotheli
cell
liver
spleen
prevent
remov
antibodysensit
cell
debr
colleagu
provid
evid
hypothesi
infus
fcc
fragment
children
itp
show
increas
platelet
count
infus
fc
receptor
blockad
theori
may
account
rapid
increas
platelet
count
ivig
infus
longterm
benefit
ivig
thu
addit
mechan
sought
one
mechan
support
anim
studi
ivig
stimul
inhibitori
fccriib
receptor
found
varieti
cell
type
includ
b
cell
turn
inhibit
antibodi
immun
function
samuelsson
colleagu
show
mous
model
itp
ivig
suppress
inhibit
antiplatelet
antibodi
product
fccriib
receptor
subsequ
ravetch
colleagu
identifi
distinct
motif
ivig
propens
engag
activ
fccriib
inhibitor
receptor
inhibit
antibodi
synthesi
distinct
properti
attribut
carbohydr
moieti
ivig
molecul
repres
total
igg
molecul
differ
coval
attach
carbohydr
glycan
igg
molecul
identifi
glycosyl
igg
essenti
bind
fcc
receptor
import
glycan
moieti
igg
molecul
attach
asparagin
asn
second
domain
constant
region
igg
molecul
use
kbxn
seruminduc
arthriti
model
mice
kaneko
show
igg
gkg
inhibit
inflammatori
arthrit
process
deglycosyl
neuraminidasetr
ivig
unabl
inhibit
inflamm
kaneko
show
ivig
enrich
sialyl
glycan
moieti
compar
inhibitori
effect
inflammatori
process
onetenth
dosag
use
intact
ivig
investig
show
inhibitori
activ
resid
igg
fc
fragment
depend
fccriib
express
effector
macrophag
anthoni
colleagu
engin
recombinantsialyl
human
fc
protein
immun
modul
activ
nativ
ivig
investig
show
action
sialyl
fc
rheumatoid
arthriti
mous
model
mediat
interact
sialyl
fc
receptor
macrophag
investig
propos
interact
sialyl
fc
produc
antiinflammatori
state
upregul
inhibitori
fccriib
receptor
effector
cell
make
cell
resist
trigger
immun
complex
suggest
dcsign
human
homolog
compar
role
antiinflammatori
effect
igg
fc
fragment
anoth
mechan
propos
yu
lennon
suggest
administr
highdos
ivig
augment
catabol
endogen
serum
igg
igg
catabol
occur
process
igg
molecul
bind
special
fc
receptor
found
endotheli
cell
eg
fcrn
protect
igg
molecul
normal
catabol
remov
plasma
process
account
long
serum
igg
halflif
day
highdos
ivig
satur
fcrn
receptor
result
acceler
catabol
autoantibodi
hansen
balthasar
support
data
rat
model
immun
thrombocytopenia
use
monoclon
antibodi
use
ivig
sever
autoimmun
inflammatori
neuropathi
present
box
fda
recent
approv
use
ivig
chronic
inflammatori
demyelin
polyneuropathi
tabl
also
show
evidencebas
efficaci
ivig
rheumat
disord
asid
mechan
involv
fccriib
inhibitori
receptor
acceler
catabol
autoimmun
antibodi
fcrn
receptor
also
propos
administr
ivig
regul
autoreact
b
cell
restor
idiotypicantiidiotyp
network
autoimmun
diseas
may
associ
defici
antiidiotyp
antibodi
believ
regul
product
activ
autoantibodi
box
kazatchkin
colleagu
show
f
ab
fragment
prepar
ivig
could
bind
sever
autoantibodi
eg
antifactor
viii
antithyroglobulin
antidna
antiintrins
factor
neutrophil
cytoplasm
antigen
thu
lead
increas
catabol
autoimmun
antibodi
prevent
induc
tissu
injuri
investig
postul
ivig
may
work
least
part
certain
autoimmun
diseas
neutral
function
activ
variou
autoantibodi
inhibit
bind
respect
autoantigen
anoth
mechan
ivig
may
benefit
autoimmun
diseas
prevent
uptak
complement
target
tissu
berger
colleagu
show
high
concentr
igg
inhibit
uptak
antibodysensit
erythrocyt
thu
inflammatori
autoimmun
process
involv
process
could
modul
ivig
therapi
situat
best
exemplifi
patient
dermatomyos
diseas
mediat
activ
deposit
membran
attack
complex
endomysi
capillari
treatment
ivig
inhibit
complementinduc
inflamm
decreas
complement
deposit
endomysi
capillari
muscl
tissu
mechan
ivig
relev
dermatomyos
also
syndrom
myasthenia
gravi
shown
box
ivig
use
mani
inflammatori
diseas
howev
evidencebas
data
sever
diseas
strong
autoimmun
disord
discuss
earlier
nevertheless
one
inflammatori
diseas
ivig
may
benefici
toxic
epiderm
necrolysi
stevensjohnson
syndrom
patient
toxic
epiderm
necrolysi
high
level
serumsolubl
fa
ligand
bind
fa
receptor
keratinocyt
induc
apoptosi
cell
death
viard
colleagu
show
antifa
antibodi
ivig
block
interact
fa
ligand
fa
receptor
keratinocyt
prevent
destruct
epithelium
ivig
contain
antibodi
sever
cellsurfac
molecul
includ
antibodi
sequenc
contain
argglyasp
motif
express
cell
surfac
matrix
protein
part
integrin
adhes
system
ivig
inhibit
adhes
b
cell
fibronectin
inhibit
platelet
aggreg
turhan
colleagu
chang
colleagu
investig
effect
ivig
mous
model
sickl
cell
acut
vasoocclus
crisi
adhes
sickl
red
blood
cell
leukocyt
caus
vasoocclus
diseas
model
highdos
ivig
given
onset
crisi
result
improv
blood
flow
prolong
surviv
investig
show
ivig
revers
acut
vasoocclus
crisi
sickl
cell
mice
inhibit
neutrophil
adhes
capillari
endotheli
cell
variou
mechan
antiinflammatori
immunomodulatori
properti
ivig
review
first
use
ivig
treatment
immun
thrombocytopenia
presum
fc
receptor
blockad
mechan
review
well
evid
valu
ivig
multipl
disord
ivig
may
yet
undiscov
immunomodul
properti
innat
adapt
immun
system
futur
advanc
includ
better
understand
mechan
action
modif
igg
molecul
enhanc
immunomodul
properti
